Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUCCESS-C: Adjuvant Docetaxel-Based Chemotherapy and Lifestyle Intervention in Early Breast Cancer
NCT00847444Phase 3Unknown
- Start
- Feb 2009
- Primary completion
- Sep 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, cyclophosphamide, epirubicin and fluorouracil in breast cancer (4 arms). Primary endpoints: Disease-Free Survival (Chemotherapy) at 60 months and Disease-Free Survival (Lifestyle) at 60 months. Status: unknown.
02
Drugs
docetaxelcyclophosphamideepirubicinfluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00847444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00847444.